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Introduction
While the focus of attention currently is on developing a vac-
cine against the Coronavirus SARS-CoV-2 to protect against 
the disease COVID-19, policymakers should prepare for the 
next challenge: uptake of the vaccine among the public. Hav-
ing a vaccine does not automatically imply it will be used. 
Compliance with the anti-H1N1 vaccine during the 2009 
influenza pandemic, for instance, was low [1], and in the 
decade since, vaccination rates have remained an issue of 
concern [2] while vaccination hesitancy has become more 
prevalent, leading to increases in disease outbreaks in mul-
tiple countries [3]. It is, therefore, important to understand 
whether or not people are willing to be vaccinated against 
COVID-19, as this can have large consequences for the suc-
cess a vaccination programme—with potentially large health 
and economic consequences. In this editorial, we provide 
some first insights into this willingness to be vaccinated, 
based on a multi-country European study [4], which hope-
fully result in more attention for this important issue.
A vaccine against COVID‑19
On April 26, the WHO counted seven COVID-19 candi-
date vaccines in the clinical evaluation phase and 82 more 
in the preclinical evaluation phase [5]. This underlines the 
unprecedented current efforts worldwide to find an effective 
vaccine against the Coronavirus SARS-CoV-2. Some expect 
that first vaccines may become available under emergency 
use protocols as soon as early 2021, given the speed and 
scale of research and development efforts globally, while 
others argue it will take longer [6–8]. In both cases, the 
development phase should be followed by large-scale vac-
cination programmes to attain herd immunity [9]. That way, 
we can protect the lives of the most vulnerable people and 
reduce the social and economic burden of the current crisis.
Vaccination programmes can lead to herd immunity 
without requiring a large proportion of the population to be 
infected. The latter is mostly seen as an undesirable option, 
given the potentially high numbers of deaths as a result of 
infection. Especially so, if the health systems are over-
whelmed by a large number of patients with severe COVID-19 
symptoms [10]. Herd immunity through vaccination, however, 
requires a sufficient proportion of the population to be vacci-
nated. While vaccination is widely recognised as an effective 
way to reduce or eliminate the burden of infectious diseases 
by health authorities and the medical community [11], its 
effectiveness also depends on the individual willingness to be 
vaccinated. This willingness could be negatively affected by 
doubts and worries that exist in the population about the safety 
and appropriateness of vaccines. This is sometimes labelled 
vaccine hesitancy [12]. If too many individuals hesitate about 
being vaccinated, herd immunity may not be reached. Besides 
objective trade-offs of costs and benefits of a vaccine, risk 
attitude, pro-social considerations, and misinformation or mis-
perceptions about a vaccine may play a role in this [2, 13, 14].
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At present, it is unclear whether a sufficient proportion 
of the population would decide to get vaccinated when a 
vaccine becomes available. In the EU, vaccine delays and 
refusals are contributing to declining immunisation rates in 
several countries and lead to increases in disease outbreaks 
[3]. Hence, and the question is whether enough Europeans 
trust the effectiveness and safety of vaccines and the health-
care system that delivers them [15].
Willingness to be vaccinated
To shed more light on the issue of willingness to be vac-
cinated, we investigated people attitudes about vaccination 
against COVID-19 in an online survey among representa-
tive samples of the population (in terms of region, gender, 
age group and education) in seven European countries 
(N = 7.662). The sample consisted of about 1.000 respond-
ents per country, and an additional 500 from the highly 
affected region Lombardy, since we expected that results 
might differ from the rest of Italy. In this first wave of the 
data collection, respondents were inquired about worries and 
beliefs about COVID-19, as well as attitudes about vaccina-
tion and their willingness to be vaccinated between 2 and 
15 April 2020 [4]. In this editorial, we provide some first 
insights into the findings, to stimulate further research and 
policy in this area.
In total, 73.9% of the 7664 participants from Denmark, 
France, Germany, Italy, Portugal, the Netherlands, and 
the UK stated that they would be willing to get vaccinated 
against COVID-19 if a vaccine would be available. A fur-
ther 18.9% of respondents stated that they were not sure, 
and 7.2% stated that they do not want to get vaccinated. As 
shown in Figs. 1 and 2, the willingness ranged from 62% in 
France to approx. 80% in Denmark and the UK. The largest 
proportions of the population opposed to a COVID-19 vacci-
nation were observed in Germany (10%) and France (10%), 
while France also has the largest group of people who were 
unsure about getting vaccinated (28%).
Looking closer, we found considerable differences in 
willingness to get vaccinated across genders and age groups 
(Fig. 3). A significantly higher proportion of men were will-
ing to get vaccinated (77.94%, Chi-squared, p < 0.001) than 
women (70.15%). The willingness to be vaccinated is largest 
among men above the age of 55, while uncertainty ranged 
between 14 and 17% across all age groups. Males who were 
unwilling to get vaccinated tended to be younger with the 
largest share of 12% among the 18–24 year olds. Similarly, 
the trend for women who were unwilling to vaccinate seems 
also to follow the age categories. The uncertainty among 
women was higher in all age groups and largest for women 
between the ages of 45 and 54 (26%).
One might argue that the group who is currently unsure 
about getting a vaccine may be the most relevant. These are 
the people who potentially can be persuaded more easily 
to get vaccinated to achieve herd immunity. Based on our 
results, these efforts could best be aimed at persons below 
the age of 55 and at females in general, where the willing-
ness is lower.
We asked respondents who were unsure about being 
vaccinated about their main reasons (Fig. 4). More than 
half (55%) said they were concerned about potential side 
effects of a vaccine, although this concern was more fre-
quent among women (36%) than men (19%). Around 15% of 
respondents stated that a vaccine might not be safe, with no 
notable differences between genders. These findings are in 
the literature on frequent reasons for vaccine hesitancy [15]. 
Looking at the open text explanations given to the category 
“other”, we saw that a common concern seems to be that 
a COVID-19 vaccine might be experimental, without any 
studies on side effects, and that the vaccine may not be safe 
for specific groups, such as for pregnant woman, people with 
pre-existing conditions like MS, allergic persons etc.
This finding highlights that while the current focus seems 
to be on developing a vaccine about ten times faster than 
Fig. 1  Proportion of respondents who stated they would be willing to 
be vaccinated against the novel coronavirus per country
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usual [7], the public should also be reassured that any vac-
cine which becomes available that quickly is safe and effec-
tive. Otherwise, there is a risk to lose the public trust in the 
particular vaccine, and coronavirus vaccination altogether 
[16], potentially compromising herd immunity.
We find a similar trend regarding the most frequently 
mentioned reasons and the gender differences for the con-
cerns about side effects among those who were not will-
ing to get vaccinated (Fig. 5). Notable gender differences 
could also be observed among those respondents who 
stated that they think COVID-19 is not dangerous to 
their health (11%), comprised of almost twice as many 
men (7%) than women (4%). Furthermore, we see that 
an overall rejection of vaccination was more than twice 
as common among women (7%) than among men (3%). 
When looking at the open text answers of respondents who 
choose other reasons (11%), we found not only concerns 
Fig. 2  Willingness to be vac-
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about safety but also comments about conspiracy theories 
and a general rejection of vaccines.
Increasing willingness to be vaccinated
The literature suggests multiple steps that could be taken by 
policymakers to decrease vaccine hesitancy and convince 
doubters to get vaccinated after all. One approach for vac-
cine advocacy suggests “vaccine adoption = access + accept-
ance” [17]. Looking at access, it is essential to translate the 
willingness to be vaccinated into actual vaccination deci-
sions. Our study measured the intention to vaccinate; this 
rate might differ from actual vaccination uptake (vaccina-
tion decision) depending on potential constraints, such as 
the price of the vaccine and the ease of access of vaccination 
sites. Vaccines should thus be available in a timely manner 
and an easily accessible way to have as little attrition as pos-
sible [12]. In the case of the coronavirus vaccine, access will 
prove quite challenging since, at the early stages of avail-
ability, the demand for this vaccine worldwide will be much 
greater than the (short-term) production capacities. Cur-
rently, about 5 billion doses of vaccine are produced yearly 
worldwide, of which 30% are seasonal flu vaccines [18]. So 
even when a vaccine becomes available, access to it will 
probably be limited in the short run. Therefore, policymak-
ers need to prepare how access can be organised equitably 
and effectively.
Our results on acceptability suggest that substantial gains 
could be made among the sizeable proportion of the popu-
lation (i.e. 18.9%) that is unsure whether they want to get 
vaccinated. If this group needs to be convinced to be vac-
cinated to get to herd immunity, clear communication about 
safety, and potential side effects of the vaccine is especially 
important. This could help to stimulate the hesitant part of 
European citizens to get vaccinated after all.
This is especially important since it is unclear whether the 
group of people who are willing to be vaccinated in itself is 
Fig. 4  Reasons given by people 
who were unsure if they would 
like to be vaccinated against 
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large enough to achieve herd immunity. The basic reproduc-
tion number R0 shows the transmission potential of diseases 
[19], i.e. to how many people the infection is expected to 
be passed on by one infected individual in a fully suscep-
tible population, on average. The herd immunity threshold 
describes the proportion of the population that needs to be 
immune, so that the infectious disease is stable (R = 1) and 
is calculated as [20]:
This means that the higher the basic reproductive number 
R0 is, the higher the herd immunity threshold becomes. A 
recent study estimated a COVID-19 R0 of around 3.87 for 
Europe [21], implying a herd immunity threshold for Europe 
of 74%. For the US, it was estimated at around 3.45, implying 
a herd immunity threshold of 71% [22]; while, a recent study 
argues these values may be lower if there is heterogeneity in 
the individual susceptibility to the virus [23]. Of course, these 
estimates are uncertain, but comparing this 71–74% threshold 
range with our results indicates that the current willingness 
levels in France, Germany and the Netherlands, in particular, 
may prove insufficient to reach this threshold.
Our survey highlighted important differences between 
citizens from European countries in terms of willingness to 
be vaccinated against COVID-19. The levels do not follow 
trends that we see in other vaccination rates, e.g. against 
measles, which are generally higher, but in most countries 
below the recommended 95% threshold [24].
Understanding which groups in the population are not 
willing to be vaccinated and why remains vital for the design 
of policy responses to vaccination hesitancy. One of the 
avenues to explore could be to emphasise the social benefits 
of vaccination more strongly so that they weigh the public 
health dimension more heavily in their decision whether 
to vaccinate [13]. A recent study, for example, found that 
people are more willing to get vaccinated when they were 
informed that this would protect others who are willing but 
unable to get vaccinated themselves [25]. Consequently, one 
of the communication strategies could be to emphasise how 
vaccination against COVID-19 helps to protect vulnerable 
members of society. Furthermore, the distribution of vacci-
nated individuals in the population matters. Pockets of non-
vaccinated groups could be highly problematic even when 
overall vaccination rates are high. Unvaccinated individu-
als may be more often in contact with other unvaccinated 
individuals than with vaccinated ones [26]. Examples of 
measles outbreaks in the Netherlands [27] and the US [28], 
for instance, show that outbreaks in particular communities 
may even occur if overall vaccination rates are high, and 
highlight the role of religious communities and travellers 
in this context.




Alternative strategies range from restrictive measures 
against those who chose not to be vaccinated to mandatory 
vaccination schemes for certain target groups or the whole 
population. Experimental evidence suggests that individuals 
under specific conditions may be willing to support man-
datory vaccination policies, but this support seems very 
sensitive to adverse events [29]. Such a policy may be less 
appropriate in the context of COVID-19.
Beyond finding a vaccine
Our findings highlight that considerable policy effort may 
be required to come from having a vaccine to adequate vac-
cination rates, especially in some countries. Targeting those 
in the population who are currently hesitant seems most 
promising and cost-effective, but this requires convincing 
evidence and clear communication on the safety and effec-
tiveness of the vaccine. This may be at odds with the cur-
rent push for having a vaccine available as soon as possible. 
A campaign emphasising the social benefits of vaccination 
could increase the willingness to be vaccinated among those 
amenable to such pro-social motives. Finally, a sizeable pro-
portion of the population indicates not to be open to vaccina-
tion. This group may remain at risk of spreading the virus 
and contracting the disease, even after herd immunity has 
been achieved. Concluding, improving our understanding 
of vaccination hesitancy in the context of COVID-19, as 
well as finding and using policies to overcome it, may be as 
important as discovering a safe and effective vaccine.
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